ALSMA

FR0014005I80

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 05:11:46 31/05/2024 pm IST			5-day change	1st Jan Change
3.82 ^EUR	+1.60%		+2.14%	+24.03%

23/01	S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023	CI
2023	S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

S.M.A.I.O S.A. has filed an IPO in the amount of €10.349994 million.

March 23, 2022 at 09:30 am IST

S.M.A.I.O S.A. has filed an IPO in the amount of €10.349994 million.

Security Name: Ordinary Shares
Security Type: Common Stock
Securities Offered: 1,868,230
PriceRange: €5.54

Latest news about SMAIO

S.M.A.I.O S.A. Announces Unaudited Group Sales Results for the Year Ended December 31, 2023	23/01	CI
S.M.A.I.O S.A. Reports Earnings Results for the Half Year Ended June 30, 2023	18/23/18	CI
S.M.A.I.O S.A. Reports Unaudited Sales Results for the First Half of 2023	18/23/18	CI
Global markets live: Gamestop, Lucid, Meta Platforms, Vodafone, Nestlé...	08/23/08
SMAIO Receives FDA 510(k) Clearance for Customized Surgery Planning Software Co-Developed with NuVasive	08/23/08	CI
S.M.A.I.O S.A. Reports Sales Results for the Year Ended December 31, 2022	17/23/17	CI
S.M.A.I.O S.A. announced that it has received funding from Nexstage AM	31/22/31	CI
S.M.A.I.O S.A. Reports Sales Results for the First Half of 2022	12/22/12	CI
Smaio Receives FDA 510(K) Clearance for “K-Rod”, Its Patient-Specific Union Rod	15/22/15	CI
S.M.A.I.O S.A. has completed an IPO in the amount of €8.94264 million.	01/22/01	CI
S.M.A.I.O S.A. has filed an IPO in the amount of €10.349994 million.	23/22/23	CI

S.M.A.I.O is specialized in the design, manufacture and marketing of implantable medical devices for the treatment of spinal pathologies. The company offers the Kheiron Spinal Fixation System, a device that incorporates a large number of implants, intended for the immobilization and stabilization of spinal segments as an adjunct to fusion of the thoracic, lumbar and/or sacral spine. In addition, S.M.A.I.O has developed the Keops and Balance Analyzer 3D surgical planning and patient database management software, and the company also offers training programs. Net sales break down by source of revenue between sales of products (95.4%) and services (4.6%). Export accounts for 54.9% of net sales.

Sector

Pharmaceuticals

Calendar

18/06/2024 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Ratings for SMAIO

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.82 EUR

Average target price

5.8 EUR

Spread / Average Target

+51.83%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
SMAIO	+24.03%	2.17Cr
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr
PFIZER, INC.	-0.45%	16TCr

Other Pharmaceuticals

SMAIO

Equities

ALSMA

FR0014005I80

Pharmaceuticals

S.M.A.I.O S.A. has filed an IPO in the amount of €10.349994 million.

Latest news about SMAIO

Chart SMAIO

Company Profile

Income Statement Evolution

Ratings for SMAIO

Analysts' Consensus

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals